193 related articles for article (PubMed ID: 21651487)
1. Fyn kinase in brain diseases and cancer: the search for inhibitors.
Schenone S; Brullo C; Musumeci F; Biava M; Falchi F; Botta M
Curr Med Chem; 2011; 18(19):2921-42. PubMed ID: 21651487
[TBL] [Abstract][Full Text] [Related]
2. Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.
Tintori C; La Sala G; Vignaroli G; Botta L; Fallacara AL; Falchi F; Radi M; Zamperini C; Dreassi E; Dello Iacono L; Orioli D; Biamonti G; Garbelli M; Lossani A; Gasparrini F; Tuccinardi T; Laurenzana I; Angelucci A; Maga G; Schenone S; Brullo C; Musumeci F; Desogus A; Crespan E; Botta M
J Med Chem; 2015 Jun; 58(11):4590-609. PubMed ID: 25923950
[TBL] [Abstract][Full Text] [Related]
3. Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors.
Poli G; Lapillo M; Granchi C; Caciolla J; Mouawad N; Caligiuri I; Rizzolio F; Langer T; Minutolo F; Tuccinardi T
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):956-961. PubMed ID: 29747534
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
5. Structure of human Fyn kinase domain complexed with staurosporine.
Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
[TBL] [Abstract][Full Text] [Related]
6. Identification of new Fyn kinase inhibitors using a FLAP-based approach.
Poli G; Tuccinardi T; Rizzolio F; Caligiuri I; Botta L; Granchi C; Ortore G; Minutolo F; Schenone S; Martinelli A
J Chem Inf Model; 2013 Oct; 53(10):2538-47. PubMed ID: 24001328
[TBL] [Abstract][Full Text] [Related]
7. Fyn Tyrosine Kinase as Harmonizing Factor in Neuronal Functions and Dysfunctions.
Matrone C; Petrillo F; Nasso R; Ferretti G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580508
[TBL] [Abstract][Full Text] [Related]
8. Role of Fyn Kinase Inhibitors in Switching Neuroinflammatory Pathways.
Marotta G; Basagni F; Rosini M; Minarini A
Curr Med Chem; 2022; 29(27):4738-4755. PubMed ID: 34939537
[TBL] [Abstract][Full Text] [Related]
9. Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes.
Jelić D; Mildner B; Kostrun S; Nujić K; Verbanac D; Culić O; Antolović R; Brandt W
J Med Chem; 2007 Mar; 50(6):1090-100. PubMed ID: 17315853
[TBL] [Abstract][Full Text] [Related]
10. Unveiling Phytoconstituents with Inhibitory Potential Against Tyrosine-Protein Kinase Fyn: A Comprehensive Virtual Screening Approach Targeting Alzheimer's Disease.
Alrouji M; Majrashi TA; Alhumaydhi FA; Zari A; Zari TA; Al Abdulmonem W; Sharaf SE; Shahwan M; Anwar S; Shamsi A; Atiya A
J Alzheimers Dis; 2023; 96(2):827-844. PubMed ID: 37899058
[TBL] [Abstract][Full Text] [Related]
11. Fyn: a novel molecular target in cancer.
Saito YD; Jensen AR; Salgia R; Posadas EM
Cancer; 2010 Apr; 116(7):1629-37. PubMed ID: 20151426
[TBL] [Abstract][Full Text] [Related]
12. Targeting Fyn Kinase in Alzheimer's Disease.
Nygaard HB
Biol Psychiatry; 2018 Feb; 83(4):369-376. PubMed ID: 28709498
[TBL] [Abstract][Full Text] [Related]
13. The Fyn kinase inhibitor, AZD0530, suppresses mouse alcohol self-administration and seeking.
Morisot N; Berger AL; Phamluong K; Cross A; Ron D
Addict Biol; 2019 Nov; 24(6):1227-1234. PubMed ID: 30536923
[TBL] [Abstract][Full Text] [Related]
14. Oligodendrocyte differentiation and signaling after transferrin internalization: a mechanism of action.
Pérez MJ; Fernandez N; Pasquini JM
Exp Neurol; 2013 Oct; 248():262-74. PubMed ID: 23797152
[TBL] [Abstract][Full Text] [Related]
15. A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies.
Irwin ME; Johnson BP; Manshouri R; Amin HM; Chandra J
Oncotarget; 2015 Sep; 6(27):23631-46. PubMed ID: 26136341
[TBL] [Abstract][Full Text] [Related]
16. SRC kinase inhibitors: an update on patented compounds.
Schenone S; Brullo C; Musumeci F; Radi M; Castagnolo D
Curr Med Chem; 2011; 18(33):5061-78. PubMed ID: 22050754
[TBL] [Abstract][Full Text] [Related]
17. Fyn is an important molecule in cancer pathogenesis and drug resistance.
Elias D; Ditzel HJ
Pharmacol Res; 2015 Oct; 100():250-4. PubMed ID: 26305432
[TBL] [Abstract][Full Text] [Related]
18. Fyn tyrosine kinase is a critical regulator of disabled-1 during brain development.
Arnaud L; Ballif BA; Förster E; Cooper JA
Curr Biol; 2003 Jan; 13(1):9-17. PubMed ID: 12526739
[TBL] [Abstract][Full Text] [Related]
19. The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Sanz-Blasco S; Bordone MP; Damianich A; Gomez G; Bernardi MA; Isaja L; Taravini IR; Hanger DP; Avale ME; Gershanik OS; Ferrario JE
Mol Neurobiol; 2018 Jun; 55(6):5125-5136. PubMed ID: 28840468
[TBL] [Abstract][Full Text] [Related]
20. Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3.
Seo HY; Jeon JH; Jung YA; Jung GS; Lee EJ; Choi YK; Park KG; Choe MS; Jang BK; Kim MK; Lee IK
Kidney Int; 2016 Dec; 90(6):1285-1297. PubMed ID: 27616741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
